5 March 2025 in Antimicrobial Agents and Chemotherapy
Chronic hepatitis B (CHB) patients receiving entecavir (ETV) treatment might develop low-level viremia (LLV), which is proven to be associated with worse clinical outcomes, such as risk of drug-related mutations, progression to cirrhosis, and even hepatocellular carcinoma. This real-world prospective study evaluated the efficacy and safety of switching from ETV to tenofovir alafenamide fumarate (TAF) in CHB patients with LLV. From August 2020 to August 2023, 351 ETV-experienced CHB patients with LLV were enrolled from eight hospitals. Patients either continued ETV or switched to TAF. The primary efficacy endpoint was the complete virological response (CVR) at week 48; the safety endpoint was the first occurrence of any clinical adverse event during the treatment; and the renal safety and change in blood lipids were also assessed. Inverse probability treatment weighting (IPTW) generated 350.9 cases in the ETV group and 351.4 cases in the TAF group. After the 48-week treatment, the CVR and ALT normalization rates in the TAF group were 75.3% and 67.8%, which were significantly higher than 11.4% and 17.1% in the ETV group ( P < 0.001). The two strategies showed comparable impact on renal function and lipid profiles, regarding low-density lipoprotein (LDL) cholesterol and the total cholesterol to high-density lipoprotein (TC/HDL) ratio. Therefore, for ETV-treated patients with LLV, switching to TAF is superior compared with continuing ETV treatment in terms of virological and biochemical response, with non-inferior renal safety and lipid profiles. CLINICAL TRIALS: This study is registered with the Chinese Clinial Trial Registry as ChiCTR2400089257 .
17 December 2025 in Antiviral Research
1 January 2025 in Annals of Saudi Medicine
BACKGROUND: Thrombocytopenia and leukopenia are common complications of alcoholic liver cirrhosis (ALC) and are associated with an increased risk of bleeding, infection and mortality. OBJECTIVES: Evaluate the effectiveness and safety of leucogen, a cysteine derivative that increases platelet (PLT) and white blood cell (WBC) counts in ALC patients. DESIGN: Retrospective SETTING: Department of hepatology, general hospital PATIENTS AND METHODS: Patients with ALC who had thrombocytopenia and/or leukopenia were enrolled between 2022 and 2023 and were divided into two groups based on their treatment: the leucogen group (20 mg, three times per day) and the non-leucogen group. MAIN OUTCOME MEASURES: The primary endpoint was an increase in PLT or WBC of ≥5% from baseline. SAMPLE SIZE: 413 patients (320 patients in the final analysis) RESULTS: In this retrospective study, 320 patients were analyzed post-propensity score matching: 160 patients each in the leucogen and non-leucogen groups. Following 3 months of treatment, the leucogen group experienced a median increase in PLT levels of 1.0×10 9 /L versus a decrease of 3.0×10 9 /L in the non-leucogen group ( P =.003), and a median increase in WBC counts of 0.1×10 9 /L compared to a decrease of 0.1×10 9 /L ( P =.006). The changes in ALT, AST, and TBIL levels were not significantly different between groups. A higher proportion of patients in the leucogen group experienced increases in both PLT (46.9% vs. 32.5%, P =.012) and WBC counts (50.0% vs. 36.2%, P =.018), and 28.1% of patients in the leucogen group had increases in both parameters, compared to 15.6% in the non-leucogen group ( P =.01). The leucogen group also demonstrated greater increases in PLT (OR 1.833; P =.009) and WBC counts (OR 1.759; P =.013) compared to the non-leucogen group. The safety profile of leucogen was favorable, with no significant adverse events reported. Leucogen was particularly beneficial for patients younger than 60 years and those with lower baseline ALT and AST levels, showing significant improvements in both PLT and WBC counts in these subgroups. CONCLUSIONS: Leucogen effectively increased PLT and WBC counts in patients with ALC, showing a favorable safety profile. LIMITATIONS: Retrospective study